For citations:
Karetnikova V.N., Kchorlampenko A.A., Kochergina A.M., Osokina A.V., Gruzdeva O.V., Golubovskaia D.P., Barbarash O.L. Cardiometabolic Effects of Empagliflozin in Patients Undergoing Elective Percutaneous Coronary Intervention for Type 2 Diabetes Mellitus. Kardiologiia. 2022;62(12):64-72. https://doi.org/10.18087/cardio.2022.12.n1838